leadf
logo-loader
viewNoxopharm Ltd

Noxopharm Ltd debuts on ASX; supported by solid trading volumes

au_medical_chart350_57a965a9340ab.jpg

Noxopharm Ltd (ASX:NOX), an Australian biotech company, listed on the ASX today after raising $6 million in an over-subscribed IPO.

The clinic-ready company is focused on commencing the first human clinical trial for its drug, NOX66.

The purpose of NOX66 is to eliminate the ability of a cancer cell to develop and maintain its drug-resistance mechanisms, something that leads to many cancer patients eventually running out of treatment options.

Graham Kelly, CEO, held various senior roles for nearly 20 years at Novogen, a $1+ billion company. Novogen attempted to develop an anti-cancer drug targeting a similar market.

At 3:00PM Sydney time, over 5 million Noxopharm shares had been traded on the ASX.

Shares issued under the IPO were priced at $0.20 and shares have traded between $0.18 and $0.20 today.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

Quick facts: Noxopharm Ltd

Price: 0.66 AUD

ASX:NOX
Market: ASX
Market Cap: $170.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Base Resources lifts production across all products as sector 'continues to...

Base Resources Limited's (LON:BSE)(ASX:BSE) Tim Carstens talks Proactive's Andrew Scott through its December quarter highlights. He says it's been a pleasing quarter with operations at Kwale continuing with its 'usual consistent production'. ''We had our mining rates up quite a bit this...

6 hours, 14 minutes ago

2 min read